A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of CRB-601, a Monoclonal Antibody against Integrin ?v?8, in Patients with Advanced Solid Tumors
Clinical Trial Grant
Awarded By
Corbus Pharmaceuticals, Inc.
Start Date
July 9, 2025
End Date
July 6, 2030
Awarded By
Corbus Pharmaceuticals, Inc.
Start Date
July 9, 2025
End Date
July 6, 2030